LNSR|EPS -$0.12|Rev $16.0M|Internet Loss $1.5M
Lensar, Inc. reported a narrower loss for the fourth quarter of 2025, posting a internet lack of $1.5M because the medical gadget maker noticed blended leads to its laser cataract surgical procedure enterprise. The corporate recorded a loss per share of $0.12, in comparison with a lack of $1.61 within the year-ago interval, representing a 92.5% enchancment.
Income totaled $16.0M for the quarter, down 4.2% from $16.7M in This autumn 2024. The decline in complete income got here regardless of robust process quantity momentum, with the corporate reporting worldwide process quantity development of 20.0% for the quarter. Lensar’s put in base reached 200 complete ALLY methods at quarter finish as the corporate continues to increase its footprint within the ophthalmology market.
The income composition confirmed diverging developments throughout enterprise traces. Process Income led the corporate’s efficiency with $9.4M in income, climbing 23.6% year-over-year as surgeons more and more utilized Lensar’s laser methods for cataract procedures. The commercial-stage firm focuses on designing and advertising and marketing laser methods for cataract remedy and associated surgical purposes.
Wall Avenue maintains a cautious stance on the inventory, with analyst consensus standing at 0 purchase, 4 maintain, and 1 promote rankings. The corporate operates within the aggressive medical gadget sector the place laser-assisted cataract surgical procedure continues to realize adoption amongst ophthalmologists looking for precision surgical outcomes.
This text was generated with the help of AI know-how and reviewed for accuracy. AlphaStreet might obtain compensation from firms talked about on this article. This content material is for informational functions solely and shouldn’t be thought of funding recommendation.
The publish Lensar, Inc. (LNSR) Reviews This autumn Earnings first appeared on Alphastreet.
